Sunshine Biopharma advances lead coronavirus drug candidate into IND-enabling studies

• Sunshine Biopharma moved its lead coronavirus drug candidate into IND-enabling studies on September 16, 2026.
• Candidate showed nanomolar in vitro potency against PLpro with broad activity across SARS-CoV-2 variants.
• Animal studies indicated strong oral bioavailability in mice, rats, dogs with preferential lung enrichment in mice, rats.
• In K18-hACE2 mice infected with SARS-CoV-2, repeated oral dosing cut pulmonary viral replication in a dose-dependent manner.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609160900ACCESSWRNAPR_____1221275) on September 16, 2026, and is solely responsible for the information contained therein.